Abstract:
Breast cancer is a prevalent malignancy in women globally, with the HER2-positive
subtype exhibiting aggressive characteristics. This review examines the prevalence of
HER2-positive breast cancer, focusing on both invasive and non-invasive forms.
HER2, a transmembrane tyrosine kinase receptor, is overexpressed in a significant
subset of breast cancers, influencing tumor behavior and prognosis. The review also
explores the impact of HER2 status on disease progression and the effectiveness of
current therapeutic strategies. Understanding the prevalence of HER2-positive
breast cancer is crucial for tailoring effective treatments and improving patient
outcomes.
